It also received a warning letter from USFDA regarding observations during the ... The company will split each share with face value of Rs 10 into two of face value Rs 5 each. Syngene International: ...

The Baltimore Biologics Drug Substance facility will serve customers across human and animal health market segments.

BANGALORE, India, March 10, 2025 /PRNewswire/ -- Syngene International Limited ... Most importantly, it increases the options we can offer our global customers, providing commercial-scale ...

In a transaction officially set to close later this month, Syngene International Limited, a contract research, development, ...

Peter Bains, CEO Designate, Syngene International Ltd., said, "With one of the largest biologics R&D teams and commercial scale manufacturing capabilities in both India and the USA, we now offer a ...

Syngene International, the contract research wing of Biocon Group, has acquired its first manufacturing facility in the US from Emergent Manufacturing Operations Baltimore. The pharma player has ...

Syngene is paying $36.5 million to acquire Emergent's shuttered biologics facility in the Bayview neighborhood of Baltimore, the Indian drugmaker said (PDF) Monday.

Peter Bains, CEO Designate, Syngene International Ltd., said, "With one of the largest biologics R&D teams and commercial scale manufacturing capabilities in both India and the USA, we now offer a ...

Peter Bains, CEO Designate, Syngene International Ltd., said, “With one of the largest biologics R&D teams and commercial scale manufacturing capabilities in both India and the USA, we now offer a ...

India-based Syngene International on Monday said it will invest around $50 million on a biologics facility in the Baltimore area, expanding its global manufacturing footprint as companies look to ...

India's Syngene International on Monday said it has acquired its first biologics facility in the United States from Emergent Manufacturing Operations Baltimore, a unit of Emergent BioSolutions, for ...